CANCER ALLIANCE PUBLISHES IMPORTANT NEW STUDY ON BREAST CANCER AND TRASTUZUMAB ACCESS IN SOUTH AFRICA

with 2 Comments

Tobeka Daki Trastuzumab Access CampaignThe Cancer Alliance today publishes an important new study BREAST CANCER and HER2+ BREAST CANCER WITH A LOOK AT TRASTUZUMAB ACCESS IN SOUTH AFRICA.

Breast cancer is the most common cancer in South Africa. It is also the second highest cancer killer of our women. At least 1 in 27 women will be diagnosed with breast cancer in their lifetime. Of these 26% will be diagnosed with HER2+ breast cancer. Adjuvant treatment (Treatment that is given in addition to the primary (initial) treatment to maximise its effectiveness) is provided in the form of trastuzumab.

To date only the originator trastuzumab Herceptin® and Herclon® are available in South Africa. The originator product Herceptin® is available in the private sector but remains unaffordable for the majority of women. Secondary patents for this medicine could block the entry of competitor products until 2026.

Click here to read more and download the full report.

2 Responses

  1. Erina
    | Reply

    Please help me. Im on Herceptin. My medical aid contributes 70% per shot which means I must pay in +- R5700 per shot every 21 days. I have about R50 000 left for oncology for 2018, which means my by 2 more shots, if Im lucky for the year. That together with my hormone tablet and all other test. I still need 7 shot this year which means +-R140 000. I can not afford this. Who can and will help us???
    Even if it part payment, it will help
    I need Herceptin!!!!!!!

    • admin
      | Reply

      Hi Erina,

      Thank you for your comment. This is precisely the problem affecting many people at present and the objective of our campaign is to reduce the price of trastuzumab (Herceptin) in South Africa. We have replied directly to you.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.